The SR One-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.
Constellation Pharmaceuticals, a US-based immuno-oncology drug developer that counts pharmaceutical firm GlaxoSmithKline as an investor, has raised $60m in an initial public offering, pricing 4 million shares at $15 each.
The company floated on the Nasdaq Global Select Market and its shares closed at $11.89 on Friday afternoon. It had originally planned to issue 5.34 million shares priced between $14 and $16 each.
Constellation is developing small-molecule therapies that will treat cancers associated with drug resistance or gene expression. They…
